Screening Postmenopausal Women for Ovarian Cancer: A Systematic Review

Journal of Obstetrics and Gynaecology Canada

Volumn 26, Issue 8, 2004, Pages 717-728

  Fung Kee Fung, Michael ^a,c,d   Bryson, Peter ^b,c,e   Johnston, Mary ^c   Charnbers, Alexandra ^c   Briere, Carmen ^p   Carey, Mark ^f   Covens, Allan ^g   Dal Bello, Dianne ^f   Daya, Dean ^h   DePetrillo, Denny ⁱ   Dodge, Jason ^j   Eisenhauer, Elizabeth ^k   Elit, Lorraine ^l   Fyles, Anthony ^m   Harrington, Wendy ^p   Hirte, Holger ^l   Kwon, Janice ⁿ   Lukka, Himu ^l   Rosen, Barry ^m   Thomas, Gillian ^g   Verma, Shailendra ^d   Yoshida, Sam ^o   more..

^a UNIVERSITY OF OTTAWA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e KINGSTON GENERAL HOSPITAL   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h HENDERSON GENERAL HOSPITAL   (Canada)

ⁱ CANCER CARE ONTARIO   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k Queen's Cancer Research Institute   (Canada)

^l JURAVINSKI CANCER CENTRE   (Canada)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ LONDON REGIONAL CANCER PROGRAM   (Canada)

^o Centre Regional De Cancerologie De Windsor   (Canada)

^p NONE

more..

Author keywords

Ca 125 Antigen; Diagnosis; Ovarian neoplasms; Population surveillance; Ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ANXIETY; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; COCHRANE LIBRARY; COHORT ANALYSIS; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; MEDLINE; OVARY CANCER; POSTMENOPAUSE; PREDICTIVE VALUE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADULT; FEMALE; INCIDENCE; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; OVARIECTOMY; OVARY; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; REVIEW; STANDARD;

ADULT; CA-125 ANTIGEN; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 7944220734     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)30643-0     Document Type: Article

References (46)

1. Canadian Cancer Statistics. Toronto: Canadian Cancer Society; National Cancer Institute of Canada; Statistics Canada 2003, 2003. National Cancer Institute of Canada, Provincial/Territorial Cancer Registries, Health Canada.
2. Holbert TR Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy. Am J Obstet Gynecol 1997, 176:1334-1338.
3. Health Canada. Cancer in Canada: estimated number of cases 1998, Health Protection Branch.
4. Bell R, Petticrew M Sheldon T.The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998, 105:1136-1147.
5. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001, 6:107-138.
6. Crump C, Mcintosh MW, Urban N, Anderson G, Karlan BY Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 2000, 9:1107-1111.
7. Bell R, Petticrew M, Luengo S, Sheldon TA Screening for ovarian cancer: a systematic review. Health Technol Assess 1998, 2:i-iv.
8. Principles and practice of screening for disease 1968, 14-39. Wilson JMG.Jungner G, World Health Organization, Geneva.
9. Sevinc A Camci C,Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003, 65:1-6.
10. Andersen MR, Peacock S Nelson J.Wilson S, Mcintosh M, Drescher C, et al. Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. Gynecol Oncol 2002, 85:3-8.
11. Browrnan GP, Levine MN, Mohide EA, RS Hayward, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995, 13:502-512.
12. Physician Data Query (PDG) of clinical trials. Available at. Accessed October 15, 2003.
13. Canadian Medical Association (CMA) Infobase. Available at. Accessed October 15, 2003.
14. National Guidelines Clearinghouse. Available at. Accessed October 15, 2003.
15. Jacobs IJ, Skates SJ, MacDonald ND, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999, 353:1207-1210.
16. Tabor A Feasibility study of a randomised trial of ovarian cancer screening. J Med Screen 1994, 1:215-219.
17. Parkes CA, Smith D, Wald NJ, Bourne TH Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen 1994, 1:209-214.
18. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 extent and ultrasonography. BMJ 1993, 306:1030-1034.
19. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obs tet Gynecol Reprod Biol 1996, 65:221-225.
20. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992, 80:14-18.
21. Grover S, Quinn MA, Weideman P, Koh H, Robinson HP, Rome R Screening for ovarian cancer using serum CA 125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995, 5:291-295.
22. Vuento MH, Stenman UH, Pirhonen JP, Makinen JI, Laippala PJ, Salmi TA Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol 1997, 64:141-146.
23. Holbert TR Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am J Obstet Gynecol 1994, 170:1699-1704.
24. Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000, 89:582-588.
25. Hayashi H, Yaginuma Y, Kitamura S, Saitou Y, Miyamoto T, Komori H, et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol Obstet Invest 1999, 47:58-64.
26. van Nagell J, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350-356.
27. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WR Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989, 299:1363-1367.
28. Millo R, Facca MC, Alberico S Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer?. Clin Exp Obstet Gynecol 1989, 16:72-78.
29. Crayford TJB, Campbell S, Bourne TH, Rawson HJ, Collins WR Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 2000, 355:1060-1063.
30. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995, 76:1214-1218.
31. Kurjak A, Shalan H, Kupesic S, Kosuta D, Sosic A, Benic S, et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994, 13:295-301.
32. Jacobs IJ, Skates S, Davies AP, Woolas RR, Jeyerajah A, Weidermann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996, 313:1355-1358.
33. Menon U, Talaat A, Rosenthal AN, MacDonald ND, Jeyarajah AR, Skates SJ, et al. Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening. Br J Obstet Gynaecol 2000, 107:165-169.
34. Einhorn N, Bast R, Knapp RC, Nilsson B, Zurawski V, Sjovall K Long term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 2000, 79:466-470.
35. Gladstone CQ Screening for ovarian cancer. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care 1994, 870-881. Health Canada, Ottawa.
36. Screening for ovarian cancer: recommendations and rationale. Ann Intern Med 1994, 121:141-142. American College of Physicians.
37. Carlson KJ, Skates SJ, Singer DE Screening for ovarian cancer. Ann Intern Med 1994, 121:124-132.
38. Ovarian cancer: screening, treatment and follow-up. JAMA 1995, 273:491-497. NIH Consensus Conference.
39. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins;l996.p. 159.
40. Ferrini R Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy. Am J Prev Med 1997, 13:444-446.
41. Pernet AL, Wardle J, Bourne TH, Whitehead MI, Campbell S, Collins WR A qualitative evaluation of the experience of surgery after false positive results in screening for familial ovarian cancer. Psychooncology 1992, 1:217-233.
42. Cull A, Fry A, Rush R, Steel CM Cancer risk perceptions and distress among women attending a familial ovarian cancer clinic. Br J Cancer 2001, 84:594-599.
43. Woolf SH, Battista RN, Anderson GM, et al. Canadian Task Force on the Periodic Health Exam 1994, xxxvii. Canada Communication Group, Ottawa.
44. Woolas RP, Conaway MR, Fengji X, Jacobs IJ, Yu YH, Daly L, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995, 59:111-116.
45. Cane P, Azen C, Lopez E, Piatt LD, Karlan BY Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol 1995, 57:240-245.
46. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.